Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Invyncible

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Invyncible
Site position #281

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 63.6/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +47
92
45
Dose & formulationCoreAge Rx +10
88
78
Clinical oversightCoreAge Rx +23
93
70
Labs & monitoringCoreAge Rx +38
90
52
FulfillmentCoreAge Rx +22
95
73
Contract termsInvyncible +10
67
77
CoreAge Rx · top barInvyncible · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxInvyncible
WeighScore89.5/10063.6/100
GradeB+C
Site position#1#281
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$149 starter program; supply length and refill cost need confirmation
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$180 per 4-week starter program (2.5 mg weekly, compounded glycine + B12)
CoverageUS only; therapy-specific state restrictions applyVaries by formulation; glycine/B12 programs exclude AR, CA, IN, MN, OR and SC
Brand-name accessNot confirmedYes
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Invyncible

Site position #281 · C

Strengths

  • Six pharmacies named with contact details
  • Patients can request a prescription copy or nominate a pharmacy
  • Public catalogs distinguish compounded products, brands and oral options
  • Refills are not automatic; payment is finalized only after physician approval

What to consider

  • Program amounts are not universal monthly prices; dose and formulation can change cost
  • Shipping cost not established on the reviewed program pages
  • State exclusions differ by formulation
  • Compounded medications are not FDA-approved

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard